ACADIA Pharmaceuticals Inc.

Total Valuation

ACADIA Pharmaceuticals Inc. carries a market capitalization of 3.67B, placing it among publicly traded companies globally. Its enterprise value stands at 2.96B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Share Statistics

ACADIA Pharmaceuticals Inc. currently has 171.09M shares outstanding.

Valuation Ratios

ACADIA Pharmaceuticals Inc. trades at a trailing price-to-earnings ratio of 10.02. The price-to-sales ratio is 3.44, and the price-to-book ratio stands at -2.08.

Enterprise Valuation

On an enterprise value basis, ACADIA Pharmaceuticals Inc. trades at an EV/EBITDA multiple of 31.97 and an EV/FCF ratio of 22.22. The EV/Sales ratio of 2.71 reflects the premium investors are willing to pay for the company's revenue stream, while the EV/EBIT multiple of 36.64 provides insight into valuation relative to core operating earnings.

Financial Position

ACADIA Pharmaceuticals Inc. maintains a current ratio of 3.59, meaning it holds 3.6x the short-term assets needed to cover near-term liabilities.

Financial Efficiency

Taxes

Over the trailing twelve months, ACADIA Pharmaceuticals Inc. has paid -260.54M in income taxes, reflecting an effective tax rate of 42.33.

Stock Price Statistics

ACADIA Pharmaceuticals Inc.'s stock has declined approximately -1.56178% over the past 52 weeks. The 50-day moving average sits at 21.77, while the 200-day moving average is 23.54.

Income Statement

Over the trailing twelve months, ACADIA Pharmaceuticals Inc. generated 1.10B in revenue and converted that into 375.65M in net income, yielding earnings per share of 2.20. EBITDA reached 92.71M, while operating income came in at 80.91M.

Balance Sheet

ACADIA Pharmaceuticals Inc. holds 851.46M in cash and equivalents against 50.79M in total debt, resulting in a net debt position of -282.21M. Total book value stands at -1.81B, with working capital of 790.49M providing operational flexibility.

Cash Flow

ACADIA Pharmaceuticals Inc. produced 123.49M in operating cash flow over the past twelve months. After subtracting -9.90M in capital expenditures, free cash flow totaled 113.59M - equivalent to 0.67 per share.

Margins

ACADIA Pharmaceuticals Inc. operates with a gross margin of 91.47, reflecting its pricing power and cost economics. The operating margin of 7.39 and net profit margin of 34.30 provide insight into operational efficiency.

Dividends & Yields

Scores

ACADIA Pharmaceuticals Inc. posts an Altman Z-Score of 6.18, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.